Published in Clin Chem Lab Med on January 01, 2006
Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun (2004) 10.03
HnRNP L stimulates splicing of the eNOS gene by binding to variable-length CA repeats. Nat Struct Biol (2003) 3.22
Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology (2003) 2.97
Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study. Circulation (2011) 2.87
Addition of milk prevents vascular protective effects of tea. Eur Heart J (2007) 2.80
Non-synonymous polymorphisms in melanocortin-4 receptor protect against obesity: the two facets of a Janus obesity gene. Hum Mol Genet (2007) 2.50
Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nat Genet (2007) 2.48
Variants in CPA1 are strongly associated with early onset chronic pancreatitis. Nat Genet (2013) 2.10
Percutaneous transfemoral management of severe secondary tricuspid regurgitation with Edwards Sapien XT bioprosthesis: first-in-man experience. J Am Coll Cardiol (2013) 2.02
Molecular targets of tea polyphenols in the cardiovascular system. Cardiovasc Res (2006) 1.92
A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. Nat Genet (2006) 1.90
Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of Mammalian proteasomes. J Biol Chem (2003) 1.87
CFTR, SPINK1, CTRC and PRSS1 variants in chronic pancreatitis: is the role of mutated CFTR overestimated? Gut (2012) 1.77
Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol (2002) 1.75
Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Circulation (2002) 1.75
One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol (2003) 1.72
Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J (2005) 1.71
Direct detection and differentiation of Legionella spp. and Legionella pneumophila in clinical specimens by dual-color real-time PCR and melting curve analysis. J Clin Microbiol (2002) 1.69
Computed tomography angiography and myocardial computed tomography perfusion in patients with coronary stents: prospective intraindividual comparison with conventional coronary angiography. J Am Coll Cardiol (2013) 1.67
Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics (2003) 1.63
Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther (2002) 1.58
Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged > or = 50 years. BJU Int (2005) 1.58
The SPINK1 N34S variant is associated with acute pancreatitis. Eur J Gastroenterol Hepatol (2008) 1.56
Tropical calcific pancreatitis: strong association with SPINK1 trypsin inhibitor mutations. Gastroenterology (2002) 1.54
Functional significance of a hereditary adenine insertion variant in the 5'-UTR of the endothelin-1 gene. Pharmacogenetics (2003) 1.51
Potent anti-inflammatory effects of low-dose proteasome inhibition in the vascular system. J Mol Med (Berl) (2009) 1.49
Endothelin-1 gene variant Lys198Asn and plasma endothelin level in obstructive sleep apnea. Cardiology (2008) 1.47
Humoral anti-proteasomal autoimmunity in dilated cardiomyopathy. Basic Res Cardiol (2010) 1.47
Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther (2004) 1.43
Influence of sex on outcome following transcatheter aortic valve implantation (TAVI): systematic review and meta-analysis. J Interv Cardiol (2014) 1.42
Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther (2002) 1.42
Evaluation of the -26G>A CC16 polymorphism in acute respiratory distress syndrome. Crit Care Med (2005) 1.40
Renal sympathetic denervation: early impact on ambulatory resistant hypertension. J Clin Hypertens (Greenwich) (2014) 1.40
KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn (2009) 1.38
Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet (2005) 1.36
Rapid detection of Yersinia pestis with multiplex real-time PCR assays using fluorescent hybridisation probes. FEMS Immunol Med Microbiol (2003) 1.28
Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. J Card Fail (2009) 1.26
Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection. Cardiovasc Res (2009) 1.26
Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system. Hypertension (2007) 1.26
Rapid presumptive identification of Burkholderia pseudomallei with real-time PCR assays using fluorescent hybridization probes. Mol Cell Probes (2005) 1.24
Evidence that paternal expression of the epsilon-sarcoglycan gene accounts for reduced penetrance in myoclonus-dystonia. Am J Hum Genet (2002) 1.24
Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: highly stereoselective formation of 17(R),18(S)-epoxyeicosatetraenoic acid. Biochem Pharmacol (2004) 1.23
The role of tea and tea flavonoids in cardiovascular health. Mol Nutr Food Res (2006) 1.22
Differentiation between Mycobacterium farcinogenes and Mycobacterium senegalense strains based on 16S-23S ribosomal DNA internal transcribed spacer sequences. J Clin Microbiol (2002) 1.20
Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol (2003) 1.20
Proteasome inhibitors: poisons and remedies. Med Res Rev (2008) 1.16
Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics (2008) 1.12
Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway. FASEB J (2004) 1.11
Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J Clin Psychopharmacol (2008) 1.11
Nontoxic proteasome inhibition activates a protective antioxidant defense response in endothelial cells. Free Radic Biol Med (2006) 1.10
Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol (2003) 1.09
Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. Br J Clin Pharmacol (2003) 1.09
The tea flavonoid epigallocatechin-3-gallate reduces cytokine-induced VCAM-1 expression and monocyte adhesion to endothelial cells. Biochem Biophys Res Commun (2004) 1.08
Downregulation of matrix metalloproteinases and collagens and suppression of cardiac fibrosis by inhibition of the proteasome. Hypertension (2004) 1.08
Parallel detection of five human herpes virus DNAs by a set of real-time polymerase chain reactions in a single run. J Clin Virol (2003) 1.08
Protective role of glutathione S-transferase P1 (GSTP1) Val105Val genotype in patients with bronchial asthma. Br J Clin Pharmacol (2004) 1.07
Telemedical Interventional Monitoring in Heart Failure (TIM-HF), a randomized, controlled intervention trial investigating the impact of telemedicine on mortality in ambulatory patients with heart failure: study design. Eur J Heart Fail (2010) 1.07
The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. Blood (2013) 1.05
Coordinated implementation of chikungunya virus reverse transcription-PCR. Emerg Infect Dis (2009) 1.03
Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant (2003) 1.03
Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment. Pharmacogenet Genomics (2008) 1.02
Relaxin-a pleiotropic hormone and its emerging role for experimental and clinical therapeutics. Pharmacol Ther (2006) 1.02
H5N1 Oseltamivir-resistance detection by real-time PCR using two high sensitivity labeled TaqMan probes. J Virol Methods (2006) 1.01
Association of CYP1A1 polymorphisms with differential metabolic activation of 17beta-estradiol and estrone. Cancer Res (2005) 1.01
Real-time PCR using hybridization probes for the rapid and specific identification of Francisella tularensis subspecies tularensis. Mol Cell Probes (2006) 1.00
MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol (2002) 0.99
Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol (2002) 0.99
Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clin Pharmacokinet (2004) 0.99
Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther (2004) 0.99
Green and black tea are equally potent stimuli of NO production and vasodilation: new insights into tea ingredients involved. Basic Res Cardiol (2008) 0.98
Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations. Eur J Clin Pharmacol (2008) 0.97
Validity of PCR with emphasis on variable number of tandem repeat analysis. Clin Biochem (2002) 0.97
Transrenal DNA as a diagnostic tool: important technical notes. Ann N Y Acad Sci (2004) 0.97
Protection of vascular cells from oxidative stress by proteasome inhibition depends on Nrf2. Cardiovasc Res (2009) 0.96
Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. Clin Pharmacol Ther (2004) 0.96
Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort ( Hypericum perforatum ). J Clin Psychopharmacol (2002) 0.96
Current diagnostic concepts to detect coronary artery disease in women. Eur Heart J (2008) 0.95
Genotyping of hepatitis C virus types 1, 2, 3, and 4 by a one-step LightCycler method using three different pairs of hybridization probes. J Clin Microbiol (2002) 0.95
The flavonoid phloretin suppresses stimulated expression of endothelial adhesion molecules and reduces activation of human platelets. J Nutr (2005) 0.95
A single nucleotide polymorphism in the human H-ras proto-oncogene determines the risk of urinary bladder cancer. Cancer Epidemiol Biomarkers Prev (2003) 0.95
MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Br J Clin Pharmacol (2004) 0.95
Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum (2007) 0.94
Maternal heart disease and pregnancy outcome: a single-centre experience. Eur J Heart Fail (2008) 0.94
MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundam Clin Pharmacol (2003) 0.94
Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists. Pharmacogenetics (2004) 0.94
Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics (2003) 0.94
Telemedicine in heart failure: pre-specified and exploratory subgroup analyses from the TIM-HF trial. Int J Cardiol (2011) 0.94
Relaxin improves TNF-α-induced endothelial dysfunction: the role of glucocorticoid receptor and phosphatidylinositol 3-kinase signalling. Cardiovasc Res (2012) 0.93
Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clin Pharmacol Ther (2005) 0.93
Fatal intracerebral mass bleeding associated with Ginkgo biloba and ibuprofen. Atherosclerosis (2003) 0.93
Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia (2004) 0.93
Impairment of immunoproteasome function by β5i/LMP7 subunit deficiency results in severe enterovirus myocarditis. PLoS Pathog (2011) 0.92
The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther (2002) 0.92
Negative inotropic mediators released from the heart after myocardial ischaemia-reperfusion. Cardiovasc Res (2002) 0.91
Correlation between serotonin uptake in human blood platelets with the 44-bp polymorphism and the 17-bp variable number of tandem repeat of the serotonin transporter. Am J Med Genet (2002) 0.91
Keratin 8 sequence variants in patients with pancreatitis and pancreatic cancer. J Mol Med (Berl) (2006) 0.91
Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther (2003) 0.90
Detection of non-tuberculous mycobacteria in hospital water by culture and molecular methods. Int J Med Microbiol (2008) 0.90